Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy

Documenti analoghi

• A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
  di: Stefan Knop, et al.
  Pubblicazione: (2024)
• Variation in immunoglobulin use and impact on survival in myeloma
  di: Khai Li Chai, et al.
  Pubblicazione: (2024)
• Multiple myeloma in Latin America: A systematic review
  di: Vania Tietsche de Moraes Hungria, et al.
  Pubblicazione: (2024)
• Multiple myeloma: A closer look at one of its faces
  di: Radu Chiriac, et al.
  Pubblicazione: (2025)
• Aberrant CD4 expression in plasmablastic transformation of multiple myeloma
  di: Kohei Shiroshita, et al.
  Pubblicazione: (2024)